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INTRODUCTION
Breast cancer is the most common cause of cancer death
and the most common type of cancer in women.1 The State
of Rio de Janeiro has the highest frequency of this disease in
Brazil.2 Breast cancer is a significant public health burden. A
combination of genetic factors and individual lifestyle habits
influences breast cancer risk and tumor behavior. Breast
cancer etiology is complex and heterogeneous in its clinical
presentation.3
TP53 (tumor protein 53) and XRCC1 (x-ray cross
complementing group 1), a tumor suppressor and a DNA
repair gene, respectively, contribute to cancer progression.
The TP53 gene may cause variation in susceptibility to
cancer and give clues about disease progression.4
Furthermore, several genes involved in DNA repair, such
as XRCC1, carry genetic polymorphisms that may lead to
alterations in DNA repair capacity and affect susceptibility
to various cancers, including breast cancer.5-7
Two of the most studied polymorphisms in the TP53 gene
are a 16 bp duplication in intron 3 and an arginine to proline
substitution in codon 72 in exon 4. This last variation alters
the structure of the protein p53,8 resulting in different
biochemical and biological properties.9 The Arg72 variant
induces apoptosis with about five times more efficiency
than the Pro72 variant.10,11 However, the Pro72 variant is
more efficient at inducing cell cycle arrest in the G1 phase,
allowing better repair of damaged DNA.12
XRCC1 is important in the base excision repair process
(BER). The gene has two common polymorphisms in codons
194 (Arg194Trp) and 399 (Arg399Gln) that affect the amino
acid sequence. Codon 194 is located in the linker region that
connects the domains that interact with poly(ADP-ribose)
polymerase (PARP) and DNA polymerase b.6 It is related to
the binding domains of various proteins including prolifer-
ating cell nuclear antigen (PCNA), apurinic/apyrimidinic
endonuclease 1 (APE1), and 8-hydroxyguanine DNA-
glycosylase (hOGG1). This area is rich in proline, serine,
arginine, and lysine residues. Hence, the change from a
positively charged Arg to a hydrophobic Trp could affect
the binding and efficient repair of DNA.13,14 Codon 399 is
located in the C-terminal domain of a breast cancer
susceptibility protein 1 (BRCT1) area. Chinese hamster
ovary cell lines that carry non-conservative amino acid
substitutions in this domain, which binds to PARP, exhibit
decreased DNA repair.15
Here we investigate the possible relationship between the
genetic background of breast cancer patients, including
TP53 and XRCC1 polymorphisms, and tumor clinical
pathological features such as tumor grade, estrogen and
progesterone receptor status, tumor size, and nodal status.
MATERIALS AND METHODS
We recruited 128 unrelated patients between May 2005
and November 2008 at the Department of Mastology,
Fernandes Figueira Institute in Rio de Janeiro (IFF-
Fiocruz/Brazil). All patients were diagnosed with infiltrat-
ing ductal carcinoma (IDC) and answered questions from a
structured questionnaire. Clinicopathological parameters
were obtained from hospital clinical records. We used the
classification of Scarff-Bloom-Richardson modified by
Elston and Ellis as a prognostic parameter and separated
the cases in two groups of increasing tumor aggressiveness:
low/intermediate with an Elston Grade (EG) of I/II and
high with an EG of III. This study was approved by the
Ethics Committee of the Fernandes Figueira Institute and all
participants signed an informed consent.
Genomic DNA was isolated from peripheral blood (n =
99) and non-tumor breast tissue (n = 29) according to
standard procedures.16 TP53 polymorphisms were detected
by amplifying genomic DNA with primers previously
described.17 XRCC1 polymorphisms were assessed by
PCR-RFLP as previously described.18 We were unable to
genotype eight samples for TP53 polymorphisms and three
for XRCC1 polymorphisms. To ensure the quality of our
genotyping results, all genotypes were confirmed by
sequencing after PCR during the standardization of the
method.
Data analysis was performed using the computer soft-
ware GraphPad Instat 3.06 for Windows (San Diego
California, USA). Fisher’s exact test was used to compare
the variables when the number of samples was equal to or
less than 5. A p value , 0.05 was defined as significant. The
observed numbers for each genotype were compared with
those expected for a population in Hardy-Weinberg
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Equilibrium by using a goodness of fit Chi-square (x2) test
applied by the Hardy-Weinberg Equilibrium calculator
program.19
RESULTS
To evaluate the association between breast cancer prog-
nosis and the genetic background of breast cancer patients,
we decided to carry out a case-case analysis on patients with
infiltrating ductal carcinoma (IDC) and with the most
studied variant alleles of the TP53 and XRCC1 genes.
Table 1 presents the demographical and clinicopatholo-
gical data for the 128 patients in our study. The principal
demographic characteristics of our patients are shown in
Table 2 as a function of breast cancer prognosis assessed by
Elston Grade classification (EG). None of the analyzed
characteristics, including age, menopausal status, family
history, or ethnicity, were differentially distributed between
the patients with EG I/II (low/intermediate aggressiveness)
and EG III (high aggressiveness). The allelic frequencies of
the TP53 polymorphisms PIN3 Ins16bp and Arg72Pro of 0.2
and 0.4, respectively, and of the XRCC1 polymorphisms
Arg194Trp and Arg399Gln of 0.07 and 0.25, respectively,
were in accordance with Hardy-Weinberg equilibrium.20-26
Then we proceeded with the association analysis between
tumor pathological characteristics and the allelic distribu-
tion of the variants (Table 3). We found a statistically
positive association with the 194Trp XRCC1 allele and EG III
(OR = 4.04; 95% CI = 1.30-12.35; p = 0.018).
DISCUSSION
Despite the advances in tumor classification and the
development of new therapies, breast cancer evolution
remains a mystery. TP53 is a very important tumor
suppressor gene and its product, the p53 protein, maintains
DNA stability and normal cellular growth. It is at the center
of several pathways that lead to cell cycle check points,
DNA repair, and apoptosis.27 The TP53 polymorphisms
PIN3 Ins16bp and Arg72Pro28-30 and the XRCC1 poly-
morphism Arg194Trp and Arg399Gln are the most studied
variants of each gene.31,32 However, since these studies are
based on case-control analysis using different populations
and methodologies, the results do not clarify the real load of
the polymorphic variants. Here we report the results of a
case-case study and determine the contribution of TP53 and
XRCC1 polymorphisms to breast cancer prognosis. The
histological grading system proposed by Scarff-Bloom-
Richardson and modified by Elston and Ellis in 199133 is
an important independent prognostic factor for invasive
breast tumors. The two groups of patients in our study were
rather homogenous in terms of age and ethnicity and our
genotyping results for XRCC1 variants Arg194Trp and
Table 1 - Sociodemographic of and tumor characteristics
in patients (n = 128).
Variables n (%)
Age (yr)
# 30 2 (1.56)
31 – 40 22 (17.19)
41 – 50 47 (36.72)
51 – 60 29 (22.66)
61 – 70 17 (13.28)
. 70 11 (8.59)
Ethnicity
White 65 (50.78)
Non-White 61 (47.66)
NDa 2 (1.56)
Menopausal status
Pre-menopausal 58 (45.31)
Post-menopausal 64 (50.00)
NDa 6 (4.69)
FH breast cancer
Negative 75 (58.59)
1˚ degree* 11 (8.59)
2˚ and/or 3˚ degrees 27 (21.10)
NDa 15 (11.72)
Tumor size
# 2 cm 57 (44.53)
. 2 cm a # 5 cm 40 (31.25)
. 5 cm 3 (2.34)
NDa 28 (21,88)
Elston Grade
I 28 (21.87)
II 61 (47.66)
III 23 (17.97)
NDa 16 (12.50)
Lymph node commitment
Negative 45 (35.16)
Positive 49 (38.28)
NDa 34 (26.56)
ER
Positive 52 (40.63)
Negative 26 (20.31)
NDa 50 (39.06)
PR
Positive 51 (39.84)
Negative 28 (21.88)
NDa 49 (38.28)
HER2
Negative 36 (28.12)
Positive 32 (25.00)
NDa 60 (46.88)
NDa = no data; ER = estrogen receptor; PR = progesterone receptor;
HER2 = human epidermal growth factor receptor type 2; FH = family
history; *mother and/or sister.
Table 2 - Demographics of the subjects by Elston Grade
status (n = 112).
Variables Elston Grade status p-value
EG III n (%) EG I/II n (%)
Age (yr)
# 30 1 (4.35) 2 (2.25)
31 – 40 1 (4.35) 17 (19.10)
41 – 50 6 (26.09) 35 (39.32) 0.260
51 – 60 9 (39.13) 20 (22.47)
61 – 70 3 (13.04) 8 (8.99)
. 70 3 (13.04) 7 (7.87)
Menopausal status
Pre-menopausal 6 (26.09) 41 (46.07)
Post-menopausal 14 (60.87) 42 (47.19) 0.200
NDa 3 (13.04) 6 (6.74)
FH breast cancer
Negative 18 (78.26) 50 (56.18)
1˚ degree 0 6 (6.74) 0.230
2˚ and/or 3˚
degrees*
3 (13.04) 20 (22.47)
NDa 2 (8.70) 13 (14.61)
Ethnicity
White 12 (52.17) 44 (49.44)
Non-White 10 (43.48) 44 (49.44) 0.540
NDa 1 (4.35) 1 (1.12)
EG = Elston Grade; NDa = no data; ER = estrogen receptor; PR =
progesterone receptor; FH = family history; * mother and/or sister.
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Arg399Gln showed the distribution expected in a Brazilian
population.23-26 Together these observations indicate that
our group of patients is adequate for a case-case study. Our
study revealed a statistically significant relationship
between the Arg194Trp genotype of XRCC1 and Elston
grade III, which indicates a poorly differentiated tumor and,
consequently, is related to increased aggressiveness of the
disease. The role of XRCC1 in efficient BER has already been
well determined6,15,16 and it is acceptable that some gene
alterations may change its biological activity and play roles
in cancer evolution. A recently published meta-analysis of
37 studies suggests that Arg399Gln is associated with a
trend of increased breast cancer risk.31 Another meta-
analysis of 10 studies on XRCC1 haplotypes Arg194Trp
and Arg399Gln showed that any conclusions are very
difficult and complex.32 Overall, no clear indication has
been obtained from such studies. Dufflot et al.34 investi-
gated the associations of polymorphisms in the genes
XRCC1, XPD, XRCC3, and RAD5 with tumor characteristics
in 94 breast cancer patients. While no polymorphisms were
found to be associated with high tumor grade or estrogen
receptor negativity, the XRCC1 Arg194Trp variant was not
studied. Bewick et al.35 found that XRCC1 Arg399Gln may
be predictive of the outcome of patients with metastatic
breast cancer treated with DNA damaging chemotherapy.
The same was observed in a study of Portuguese patients.36
The authors investigated the possible influence of DNA
repair polymorphisms on breast cancer clinicopathological
features and described a possible correlation between the
Gln/Gln genotype of XRCC1 Arg399Gln and less aggressive
tumors, which differs from our observations. Again, the
authors did not analyze the Arg194Trp variant.
In summary, our study reveals that the XRCC1 Arg194Trp
variant is positively associated with breast tumors of Elston
grade III, which is a measure of high tumor aggressiveness.
However, this initial analysis involves a small sample size,
which may contribute to low statistical power. Our findings
indicate that further investigations are needed on a larger
group to clarify the influence of the Arg194Trp XRCC1
polymorphism in breast cancer development and prognosis.
REFERENCES
1. Shu XO, Cai Q, Gao YT, Wen W, Jin F, Zheng W. A population-based
case-control study of the Arg399Gln polymorphism in DNA repair gene
XRCC1 and risk of breast cancer. Cancer Epidemiol Biomarkers Prev.
2003;12:1462-7.
2. Ministe´rio da Sau´de. Instituto Nacional de Caˆncer – MS/INCA. (2009).
Estimativa 2010: Incideˆncia de caˆncer no Brasil. Available at: ,http://
www.inca.gov.br/estimativa/2010/..
3. Kubba AA. Breast cancer and the pill. JRSM. 2003;96:280-3, doi: 10.1258/
jrsm.96.6.280.
4. Bond GL, Hu W, Bond EE, Robins H, Lutzker SG, Arva NC, et al. A
single nucleotide polymorphism in the MDM2 promoter attenuates the
p53 tumor suppressor pathway and accelerates tumor formation in
humans. Cell. 2004;119:591-602, doi: 10.1016/j.cell.2004.11.022
Table 3 - Associations between TP53 and XRCC1 polymorphisms and tumor characteristics
Variables TP53 XRCC1
PIN 3 Arg72Pro Arg194Trp Arg399Gln
1.1 1.2 + 2.2 Arg/Arg Arg/Pro + Pro/Pro Arg/Arg Arg/Trp + Trp/Trp Arg/Arg Arg/Gln + Gln/Gln
Tumor size
(n = 92)
# 2 cm 34 20 18 36 51 7 29 29
. 2 cm 25 13 15 23 34 6 23 17
OR (95% CI) 1.00 (ref.) 0.88 (0.37 – 2.11) 1.00 (ref.) 0.77 (0.32 – 1.82) 1.00 (ref.) 1.29 (0.40 – 4.16) 1.00 (ref.) 0.79 (0.33 – 1.66)
ap 0.828 0.660 0.765 0.539
EG (n = 104)
I / II 55 27 28 54 78 9 48 39
III 12 10 8 14 15 7 13 9
OR (95% CI) 1.00 (ref.) 1.70 (0.65 – 4.42) 1.00 (ref.) 0.91 (0.34 – 2.42) 1.00 (ref.) 4.04 (1.30 – 12.35) 1.00 (ref.) 0.85 (0.33 – 2.20)
ap 0.320 1.000 0.018 0.813
Lymph node
(n = 88)
Negative 28 15 15 28 37 8 28 17
Positive 28 17 15 30 42 6 23 25
OR (95% CI) 1.00 (ref.) 1.13 (0.47 – 2.70) 1.00 (ref.) 1.07 (0.44 – 2.59) 1.00 (ref.) 0.66 (0.21 – 2.08) 1.00 (ref.) 1.79 (0.78 – 4.09)
ap 0.827 1.000 0.568 0.212
ER (n = 72)
Positive 33 15 20 28 43 8 26 25
Negative 16 8 9 15 21 4 16 9
OR (95% CI) 1.00 (ref.) 1.10 (0.39 – 3.13) 1.00 (ref.) 1.19 (0.43 – 3.25) 1.00 (ref.) 1.02 (0.28 – 3.79) 1.00 (ref.) 0.58 (0.22 – 1.56)
ap 1.000 0.802 1.000 0.332
PR (n = 73)
Positive 32 15 18 29 43 7 25 25
Negative 18 8 11 15 22 5 17 10
OR (95% CI) 1.00 (ref.) 0.95 (0.34 – 2.67) 1.00 (ref.) 0.85 (0.32 – 2.24) 1.00 (ref.) 1.40 (0.40 – 4.91) 1.00 (ref.) 0.59 (0.23 – 1.53)
ap 1.000 0,805 0.744 0.341
HER2 (n = 63)
Negative 27 7 17 17 32 4 19 17
Positive 17 12 9 20 25 7 20 12
OR (95% CI) 1.00 (ref.) 2.72 (0.89 – 8.28) 1.00 (ref.) 2.22 (0.79 – 6.26) 1.00 (ref.) 2.24 (0.59 – 8.52) 1.00 (ref.) 0.67 (0.25 – 1.77)
ap 0.100 0.199 0.325 0.468
ER = estrogen receptor; PR = progesterone receptor; ap = Fisher’s exact test (common homozygote x heterozygote + rare homozygote); OR = odds ratio;
CI = confidence interval.
CLINICS 2011;66(6):1097-1100 TP53 and XRCC1 polymorphisms in breast cancer
Rodrigues MS et al.
1099
5. Goode EL, Ulrich CM, Potter JD. Polymorphisms in DNA repair genes
and associations with cancer risk. Cancer Epidemiol Biomarkers Prev.
2002;11:1513–30.
6. Seedhouse C, Bainton R, Lewis M, Harding A, Russell N, Das-Gupta E.
The genotype distribution of the XRCC1 gene indicates a role for base
excision repair in the development of therapy-related acute myeloblastic
leukemia. Blood. 2002;100:3761-6, doi: 10.1182/blood-2002-04-1152
7. De Ruyck K, Szaumkessel M, De Rudder I, Dehoorne A, Vral A, Claes K,
et al. Polymorphisms in base-excision repair and nucleotide-excision
repair genes in relation to lung cancer risk. Mutat Res. 2007;631:101-10,
doi:10.1016/j.mrgentox.2007.03.010.
8. Thomas M, Kalita A, Labrecque S, Pim D, Banks L, Matlashewski G. Two
polymorphic variants of wild-type p53 differ biochemically and
biologically. Mol Cell Biol. 1999;19:1092-100.
9. Langerød A, Bukholm IR, Brega˚rd A, Lønning PE, Andersen TI, Rognum
TO, et al. The TP53 codon 72 polymorphism may affect the function of
TP53 mutations in breast cancer but not in colorectal carcinomas. Cancer
Epidemiol Biomarkers Prev. 2002;11:1684-8.
10. Toyama T, Zhang Z, Nishio M, Hamaguchi M. Association of TP53
codon 72 polymorphism and the outcome of adjuvant therapy in breast
cancer patients. Breast Cancer Res. 2007;9:R34, doi: 10.1186/bcr1682.
11. Dumont P, Leu JIJ, Della Pietra III AC, George DL, Murphy M. The
codon 72 polymorphic variants of p53 have markedly different apoptotic
potential. Nature genetics. 2003;33:357-65, doi: 10.1038/ng1093.
12. Øersted DD, Bojersen SE, Tybjaerg-Hansen A, Nordestgaard BG. Tumor
suppressor p53 Arg72Pro polymorphism and longevity, cancer survival,
and risk of cancer in the general population. JEM. 2007;204:1295-1301,
doi: 10.1084/jem.20062476.
13. Ladiges WC. Mouse models of XRCC1 DNA repair polymorphisms and
cancer. Oncogene. 2006;25:1612-1619, doi: 10.1038/sj.onc.1209370.
14. Hu Z, Ma H, Chen F, Wei Q, Shen H. XRCC1 Polymorphisms and cancer
risk: A meta-analysis of 38 case-control studies. Cancer Epidemiol
Biomarkers Prev. 2005;14:1810-8, doi: 10.1158/1055-9965.EPI-04-0793.
15. Shen MR, Jones IM, Mohrenweiser H. Nonconservative amino acid
substitution variants exist at polymorphic frequency in DNA repair
genes in healthy humans. Cancer Res. 1998;58:604-608.
16. Sambrook J, Fritschi EF, Maniatis T. Molecular cloning: a laboratory
manual. New York: Cold Spring Harbor Laboratory Press. 1989.
17. Lotsch PF. Caracterizac¸a˜o Molecular do Caˆncer de Mama em Mulheres
Brasileiras: o papel dos genes TP53, MDM2 e XRCC1. 2008. 132f. Tese
(Doutorado) – Universidade do Estado do Rio de Janeiro. Programa de
Po´s Graduac¸a˜o em Biologia (Biocieˆncias Nucleares).
18. Deligezer U, Dalay N. Association of the XRCC1 gene polymorphisms
with cancer risk in Turkish breast cancer patients. Exp Mol Med.
2004;36:572-5.
19. OEGE (Online Encyclopedia for Genetic Epidemiology studies). Hardy-
Weinberg equilibrium calculator. Available at: ,http://www.oege.org/
software/hwe-mr-calc.shtml., 2008.
20. Costa S, Pinto D, Pereira D, Rodrigues H, Cameselle-Teijeiro J, Medeiros R,
et al. Importance of TP53 codon 72 and intron 3 duplication 16bp
polymorphisms in prediction of susceptibility on breast cancer. BMC
Cancer. 2008;8:32, doi: 10.1186/1471-2407-8-32.
21. Cavallone L, Arcand SL, Maugard C, Ghadirian P, Mes-Masson AM,
Provencher D, et al. Haplotype analysis of TP53 polymorphisms,
Arg72Pro and Ins16, in BRCA1 and BRCA2 mutation carriers of
French Canadian descent. BMC Cancer 2008;8:96 doi: 10.1186/1471-
2407-8-96.
22. Pinto GR, Yoshioka FKN, Silva RLL, Clara CA, Santos MJ, Almeida JRW,
et al. Prognostic value of TP53 Pro47Ser and Arg72Pro single nucleotide
polymorphisms and the susceptibility to gliomas in individuals from
Southeast Brazil. Genet Mol Res. 2008;7:207-16, doi: 10.4238/vol7-
1gmr415.
23. Rossit ARB, Cabral IR, Hackel C, Da Silva RCMA, Froes NDTC, Abdel-
Rahman SZ. Polymorphisms in the DNA repair gene XRCC1 and
susceptibility to alcoholic liver cirrhosis in older Southeastern Brazilians.
Cancer Lett. 2002;180:173-82, doi: 10.1016/S0304-3835(02)00029-0.
24. Duarte MC, Colombo J, Rossit AR, Caetano A, Borim AA, Wornrath D,
Silva AE. Polymorphisms of DNA repair genes XRCC1 and XRCC3,
interaction with environmental exposure and risk of chronic gastritis and
gastric cancer. World J Gastroenterol. 2005;11:6593-600.
25. Canalle R, Andrade VSS, Scrideli CA, Queiroz RGP, Tone LG.
Polymorphisms in the thymidylate synthase promoter and the DNA
repair genes XRCC1 and XPD in a Brazilian population. Environ Mol
Mutagen. 2006;47:725-32, doi: 10.1002/em.20269.
26. Falagan-Lotsch P, Rodrigues MS, Esteves V, Vieira R, Amendola LC,
Pagnoncelli D, et al. XRCC1 gene polymorphisms in a population sample
and in women with a family history of breast cancer from Rio de Janeiro
(Brazil). Genet Mol Biol. 2009;32:255-9, doi: 10.1590/S1415-
47572009000200008.
27. Olivier M, Hollstein M, Hainaut P. TP53 Mutations in Human Cancers:
Origins, Consequences, and Clinical Use, Cold Spring Harb Perspect Biol
2010;2:a001008.
28. Francisco G, Menezes PR, Eluf-Neto J, Chammas R. Arg72Pro TP53
polymorphism and cancer susceptibility: A comprehensive meta-
analysis of 302 case-control studies. Int J Cancer. 2010 Sep 30. [Epub
ahead of print], doi 10.1002/ijc.25710.
29. Zhang Z, Wang M, Wu D, Wang M, Tong N, Tian Y, et al. P53 codon 72
polymorphism contributes to breast cancer risk: a meta-analysis based
on 39 case–control studies. Breast Cancer Res Treat. 2010;120:509-17. doi:
10.1007/s10549-009-0480-4.
30. Hu Z, Li X, Qu X, He Y, Ring BZ, Song E, et al. Intron 3 16 bp duplication
polymorphism of TP53 contributes to cancer susceptibility: a meta-
analysis. Carcinogenesis. 2010;31:643–7. Epub 2010 Jan 20, doi: 10.1093/
carcin/bgq018.
31. Huang Y, Li L, Yu L. XRCC1 Arg399Gln, Arg194Trp and Arg280His
polymorphisms in breast cancer risk: a meta-analysis. Mutagenesis.
2009;24:331–9, doi: 10.1093/mutage/gep013.
32. Saadat M. Haplotype analysis of XRCC1 (at codons 194 and 399) and
susceptibility to breast cancer, a meta-analysis of the literatures. Breast
Cancer Res Treat. 2010;124:785-91. Epub 2010 Apr 17, doi: 10.1007/
s10549-010-0895-y.
33. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I.
The value of histological grade in breast cancer: experience from a large
study with long-term follow-up. Histopathology. 1991;19:403-10, doi: 10.
1111/j.1365-2559.1991.tb00229.x.
34. Dufloth RM, Arruda A, Heinrich JKR, Schmitt F, Zeferino LC. The
investigation of DNA repair polymorphisms with histopathological
characteristics and hormone receptors in a group of Brazilian women
with breast cancer. Genet Mol Res. 2008;7:574-82, doi: 10.4238/vol7-
3gmr376.
35. Bewick MA, Conlon MSC, Lafrenie RM. Polymorphisms in XRCC1,
XRCC3, and CCND1 and Survival After Treatment for Metastatic Breast
Cancer. J Clin Oncol. 2006;24:5645-51, doi: 10.1200/JCO.2006.05.9923.
36. Costa S, Pinto D, Pereira D, Rodrigues H, Cameselle-Teijeiro J, Medeiros R,
et al. XRCC1 Arg399Gln and RAD51 50UTR G135C polymorphisms and
their outcome in tumor aggressiveness and survival of Portuguese breast
cancer patients. Breast Cancer Res Treat. 2008;109:183–5, doi: 10.1007/
s10549-007-9637-1.
TP53 and XRCC1 polymorphisms in breast cancer
Rodrigues MS et al.
CLINICS 2011;66(6):1097-1100
1100
